Management and Survival of Pleural Mesothelioma: A Record Linkage Study

被引:7
作者
Carioli, Greta [1 ]
Bonifazi, Martina [2 ,3 ]
Rossi, Marta [1 ]
Zambelli, Alberto [4 ]
Franchi, Matteo [5 ]
Zocchetti, Carlo [6 ]
Gasparini, Stefano [2 ,3 ]
Corrao, Giovanni [5 ]
La Vecchia, Carlo [1 ]
Negri, Eva [7 ]
机构
[1] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy
[2] Univ Politecn Marche, Dept Biomed Sci & Publ Hlth, Ancona, Italy
[3] Azienda Osped Univ Osped Riuniti, Dept Internal Med, Pulm Dis Unit, Ancona, Italy
[4] Osped Papa Giovanni XXIII, Dept Med Oncol, Bergamo, Italy
[5] Univ Milano Bicocca, Dept Stat & Quantitat Methods, Lab Healthcare Res & Pharmacoepidemiol, Milan, Italy
[6] RESISS Ric & Sanita & Salute, Gallarate, Italy
[7] Univ Milan, Dept Biomed & Clin Sci, Via GB Grassi 74, IT-20157 Milan, Italy
关键词
Pleural neoplasm; Mesothelioma; Survival; Cohort study; Management; MALIGNANT MESOTHELIOMA; DIAGNOSIS; COHORT; FEASIBILITY; GUIDELINES; MORTALITY; SAFETY; UPDATE; TRIAL;
D O I
10.1159/000486578
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Pleural mesothelioma (PM) is a rare, highly lethal tumor. A definite consensus on its management has yet to be established. Objectives: To assess management, overall survival (OS), and their predictors in a cohort of patients from Lombardy, the largest Italian region (about 10 million inhabitants). Methods: Through a record linkage between Lombardy health care administrative databases, we identified patients diagnosed with PM in 2006-2011 without history of cancer, evaluating their management. OS from PM diagnosis was estimated using the Kaplan-Meier method. Predictors of OS and of treatment were assessed using Cox regression models with time-dependent covariates when appropriate. Results: Out of 1,326 patients, 754 (56.9%) received treatment for PM: 205 (15.5%) underwent surgery, and 696 (52.5%) used chemotherapy. Surgery was spread across several hospitals, and most patients diagnosed in nonspecialized centers (70%) underwent surgery in the same centers. Age at diagnosis was a strong inverse determinant of surgery. Determinants of receiving chemotherapy were younger age, a more recent first diagnosis, and first diagnosis in a specialized center. OS was 45.4% at 1 year, 24.8% at 2 years, and 9.6% at 5 years (median 11 months). OS decreased with age, and was higher for those who underwent surgery, but not for those treated with chemotherapy. Conclusions: Management of PM varied widely in clinical practice, and significant predictors of treatment were younger age and recent diagnosis, though a high proportion of patients were not treated. Patients were treated in various hospitals, indicating the importance of concentrating serious rare neoplasms in Comprehensive Cancer Centers (as recognized by the Italian Health Ministry). (C) 2018 S. Karger AG, Basel
引用
收藏
页码:405 / 413
页数:9
相关论文
共 33 条
[1]   Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial [J].
Alley, Evan W. ;
Lopez, Juanita ;
Santoro, Armando ;
Morosky, Anne ;
Saraf, Sanatan ;
Piperdi, Bilal ;
van Brummelen, Emilie .
LANCET ONCOLOGY, 2017, 18 (05) :623-630
[2]   Malignant Mesothelioma Diagnosis [J].
Arif, Qudsia ;
Husain, Aliya N. .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2015, 139 (08) :978-980
[3]   Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro [J].
Baas, P. ;
Fennell, D. ;
Kerr, K. M. ;
Van Schil, P. E. ;
Haas, R. L. ;
Peters, S. .
ANNALS OF ONCOLOGY, 2015, 26 :V31-V39
[4]   Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment [J].
Bibby, Anna C. ;
Tsim, Selina ;
Kanellakis, Nikolaos ;
Ball, Hannah ;
Talbot, Denis C. ;
Blyth, Kevin G. ;
Maskell, Nick A. ;
Psallidas, Ioannis .
EUROPEAN RESPIRATORY REVIEW, 2016, 25 (142) :472-486
[5]  
Boffetta P, J GLOB ONCOL, DOI [101200/JGO2017010116, DOI 10.1200/JGO2017010116]
[6]   New therapeutic strategies for malignant pleural mesothelioma [J].
Bonelli, Mara A. ;
Fumarola, Claudia ;
La Monica, Silvia ;
Alfieri, Roberta .
BIOCHEMICAL PHARMACOLOGY, 2017, 123 :8-18
[7]   Bevacizumab in Clinical Practice: Prescribing Appropriateness Relative to National Indications and Safety [J].
Bonifazi, Martina ;
Rossi, Marta ;
Moja, Lorenzo ;
Scigliano, Vincenzo Davide ;
Franchi, Matteo ;
La Vecchia, Carlo ;
Zocchetti, Carlo ;
Negri, Eva .
ONCOLOGIST, 2012, 17 (01) :117-124
[8]   Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma? [J].
Bovolato, Pietro ;
Casadio, Caterina ;
Bille, Andrea ;
Ardissone, Francesco ;
Santambrogio, Luigi ;
Ratto, Giovanni Battista ;
Garofalo, Giuseppe ;
Bedini, Amedeo Vittorio ;
Garassino, Marina ;
Porcu, Luca ;
Torri, Valter ;
Pastorino, Ugo .
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (03) :390-396
[9]   Consensus Report of the 2015 Weinman International Conference on Mesothelioma [J].
Carbone, Michele ;
Kanodia, Shreya ;
Chao, Ann ;
Miller, Aubrey ;
Wali, Anil ;
Weissman, David ;
Adjei, Alex ;
Baumann, Francine ;
Boffetta, Paolo ;
Buck, Brenda ;
de Perrot, Marc ;
Dogan, A. Umran ;
Gavett, Steve ;
Gualtieri, Alessandro ;
Hassan, Raffit ;
Hesdorffer, Mary ;
Hirsch, Fred R. ;
Larson, David ;
Mao, Weimin ;
Masten, Scott ;
Pass, Harvey I. ;
Peto, Julian ;
Pira, Enrico ;
Steele, Ian ;
Tsao, Anne ;
Woodard, Gavitt Alida ;
Yang, Haining ;
Malik, Shakun .
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (08) :1246-1262
[10]   A validation study of a new classification algorithm to identify rheumatoid arthritis using administrative health databases: case-control and cohort diagnostic accuracy studies. Results from the RECord linkage On Rheumatic Diseases study of the Italian Society for Rheumatology [J].
Carrara, Greta ;
Scire, Carlo A. ;
Zambon, Antonella ;
Cimmino, Marco A. ;
Cerra, Carlo ;
Caprioli, Marta ;
Cagnotto, Giovanni ;
Nicotra, Federica ;
Arfe, Andrea ;
Migliazza, Simona ;
Corrao, Giovanni ;
Minisola, Giovanni ;
Montecucco, Carlomaurizio .
BMJ OPEN, 2015, 5 (01)